Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Sep;23(9):1116-1118.
doi: 10.1016/S1470-2045(22)00504-6.

Inhibiting TGF-β to increase response rates to chemoradiotherapy in rectal cancer

Paul B Romesser  1 , J Joshua Smith  2
Affiliations
Comment

Inhibiting TGF-β to increase response rates to chemoradiotherapy in rectal cancer

Paul B Romesser et al. Lancet Oncol. 2022 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

JJS received travel support from Intuitive Surgical for fellow education (2015), served as a clinical advisor for Guardant Health (2019), served as a clinical advisor for Foundation Medicine (2022), and served as a consultant and speaker for Johnson & Johnson (2022). PBR reports prior research funding from and is a consultant for EMD Serono.

Comment on

  • Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial.
    Yamazaki T, Gunderson AJ, Gilchrist M, Whiteford M, Kiely MX, Hayman A, O'Brien D, Ahmad R, Manchio JV, Fox N, McCarty K, Phillips M, Brosnan E, Vaccaro G, Li R, Simon M, Bernstein E, McCormick M, Yamasaki L, Wu Y, Drokin A, Carnahan T, To Y, Redmond WL, Lee B, Louie J, Hansen E, Solhjem MC, Cramer J, Urba WJ, Gough MJ, Crittenden MR, Young KH. Yamazaki T, et al. Lancet Oncol. 2022 Sep;23(9):1189-1200. doi: 10.1016/S1470-2045(22)00446-6. Epub 2022 Aug 8. Lancet Oncol. 2022. PMID: 35952709 Clinical Trial.

Publication types

Substances

LinkOut - more resources